BIONTECH SE SPON. ADRS 1
Commented by Armin Schulz on April 9th, 2025 | 07:00 CEST
From diabetes to cancer: How Novo Nordisk, NetraMark, and BioNTech are reinventing medicine
The medicine of tomorrow is being written today – with algorithms that personalize therapies, mRNA vaccines that fight cancer, and drugs that conquer chronic diseases. While AI is revolutionizing clinical trials and shifting billion-dollar markets, biotech pioneers are fighting for dominance in precision medicine. Who is driving this transformation? Three companies are in the spotlight: Novo Nordisk, a pioneer in the fight against diabetes and obesity; NetraMark, whose AI is decoding clinical trials; and BioNTech, which is redefining oncology with mRNA. Their innovations are not just dreams of the future – they are already changing how lives are saved and extended.
Read
Commented by André Will-Laudien on April 1st, 2025 | 07:20 CEST
Was that the Trump crash? Nevertheless, steeply upwards with Evotec, Bayer, BioNTech, Defence Therapeutics, or Valneva?
Since November 2024, Donald Trump has driven the markets sharply upward - his controversial new presidency was largely celebrated by investors. Now, his leadership feels somewhat unsettling, with fires seemingly being set again at every corner. The new president is acting more imperiously than ever, with Panama, Canada, and Greenland verbally on the agenda as the next US states. Meanwhile, the US administration is facing a considerable deficit, which is to be addressed by drastically reducing the size of the public sector and introducing tariffs. Unsurprisingly, interest rates are now rising sharply, which is a reason for weaker prices in the biotech sector. However, the sector has done its homework and is emerging from a three-year downturn. Are we now at buying levels?
Read
Commented by Fabian Lorenz on March 25th, 2025 | 07:00 CET
Takeover speculation and buy recommendations: Buy Bayer, BioNTech, and BioNxt Solutions stock after a 150% rally?
While takeover speculations are currently on pause for Evotec, they are gaining momentum for BioNxt Solutions. The Company aims to achieve significant milestones in the next 60 days on the road to marketing its lead product for treating multiple sclerosis and expanding into the billion-dollar anti-aging market. Even after the 150% rally, BioNxt shares are not expensive. The BioNTech share has corrected sharply in 2025. However, positive analyst comments could now herald a turnaround. Will the oncology pipeline lead to a breakthrough? On the other hand, Bayer is facing a significant defeat in USD. Further billion-dollar payments are looming. Analysts remain skeptical.
Read
Commented by Stefan Feulner on March 24th, 2025 | 07:20 CET
Bayer, Vidac Pharma, BioNTech – Setbacks and New Standards
Glyphosate and no end in sight. Bayer's 2018 acquisition of US agricultural company Monsanto continues to develop into a billion-dollar grave, with a court again ruling against the Leverkusen-based company. Billions in revenue also disappeared from the books of vaccine manufacturer BioNTech after the COVID-19 pandemic subsided. In contrast, an innovative biopharmaceutical company is setting new standards in treating pediatric brain tumors.
Read
Commented by Armin Schulz on March 18th, 2025 | 07:00 CET
Bayer, Vidac Pharma, BioNTech – Making money with biotech and pharmaceutical innovations
More and more investors are betting on companies that are leaving traditional therapeutic paths to rethink cancer, chronic inflammation, or nutritional issues. While some corporations struggle with their balance sheets due to mountains of debt and patent expirations, others are quietly developing technologies that crack the metabolic code of diseases. Whether anti-aging tests from saliva samples, mRNA-based cancer cocktails, or active ingredients that overcome the blood-brain barrier – the stock market rewards those who combine research success with strategic risk-taking. But which companies have what it takes to develop the blockbusters of tomorrow? Let's take a closer look at three companies.
Read
Commented by Armin Schulz on March 3rd, 2025 | 07:40 CET
Novo Nordisk, NetraMark Holdings, BioNTech – How three pioneers are paving the way for tomorrow's medicine
On January 6, 2025, the FDA announced new guidelines for AI-powered clinical trials to accelerate the approval of life-saving therapies. This has put a spotlight on companies that combine technology and biotechnology. They are addressing pressing challenges: chronic widespread diseases, complex cancer progression, and inefficient drug development. With artificial intelligence, mRNA platforms, and strategic alliances, they are revolutionizing not only therapies but also the way pharmaceutical companies research and scale up. However, the road is rocky – regulatory hurdles, supply bottlenecks, and the race for the next blockbuster shape their stories. Who are the players disrupting billion-dollar markets with innovative approaches?
Read
Commented by André Will-Laudien on February 27th, 2025 | 07:50 CET
Attention – Biotech is taking off! Evotec, Vidac Pharma, BioNTech, and Novo Nordisk in focus
With new index highs and huge daily trading volumes, the biotech sector has been back in the spotlight for several weeks. At Evotec, the personnel merry-go-round continues, while BioNTech has announced an acquisition in the oncology field. After the big crash in Novo Nordisk shares, the first share buybacks are now taking place, but growth rates have been revised downwards. Vidac Pharma has just completed a roadshow and will present its latest progress at the Sachs Health Science CEOs Forum in Zurich. Share prices across the sector appear to have turned in the last quarter. It is now time for investors to take a closer look again. We offer a few insights.
Read
Commented by Fabian Lorenz on February 20th, 2025 | 07:30 CET
Multiplier potential with AI newcomer NetraMark! Palantir and BioNTech in one share!
"Game changer!" "Quantum leap!" "Revolution!" Experts use numerous superlatives to describe the possibilities of Artificial Intelligence (AI) in medicine. What is certain is that AI offers tremendous potential to develop new medications faster and more cost-effectively. Pharmaceutical companies can save billions, and patients can be cured more quickly. The market for AI in medicine is expected to see significant double-digit growth rates in the coming years. NetraMark Holdings aims to profit from this megatrend. The AI specialist is on the verge of a breakthrough and is starting 2025 with a software update, an important partnership, and reinforcements in top management. The share price has jumped but remains a hidden gem and is anything but expensive. There is significant upside potential!
Read
Commented by Fabian Lorenz on February 13th, 2025 | 07:10 CET
ACQUISITION?! Renk, BioNTech, and Biotech Highflyer Vidac Pharma
Is Renk about to be taken over? Quite possible. The Company, known for its transmissions for the Leopard tank, has a new major shareholder. And it turns out to be none other than KNDS – the maker of the Leopard 2 tank. The Renk share price reacted with a jump of 10%. Is there more to come? Vidac Pharma is also frequently mentioned as a potential takeover candidate. Like BMW, the Company is working on a "new class". But in this case, it is to save human lives. To this end, last year's biotech highflyer aims to revolutionize cancer treatment. Experts believe that a multiplication of the share price is possible. BioNTech is also fighting cancer. In addition to its own research, the German company is strategically focusing on acquisitions. Another one has just been completed. What is next?
Read
Commented by Armin Schulz on January 22nd, 2025 | 07:00 CET
Evotec, Vidac Pharma, BioNTech – Profiting from the fight against cancer
It has been clear for some time that cancer can affect anyone, and not just since King Charles and Princess Kate made their battles with cancer public. The market is growing, and today, revenues in this area are already in the billions. This is driven by an aging population and increasingly unhealthy lifestyles. The margins for manufacturers of cancer drugs are often in the high double-digit percentage range. It is no wonder that companies are focusing on the fight against cancer. Developing a medication that reliably defeats the disease could result in a genuine blockbuster. In 2023, around USD 223 billion was spent on cancer drugs worldwide. We are looking at three companies striving to cure cancer and claim their share of this lucrative market.
Read